GLP-1 drugs increase healthcare costs for obese patients
Healthcare costs for US obesity patients rise with GLP-1 drugs despite their weight-loss benefits.
As competition heats up, Novo Nordisk’s share price declines
Novo Nordisk's share price dropped 19% amidst growing competition from Eli Lilly in the diabetes and weight-loss drug market.